138 Shared frameshift neoantigens are expressed throughout mismatch repair deficient cancer development and are recognized by tissue infiltrating T cells that are dysregulated in advanced lesions

138 Shared frameshift neoantigens are expressed throughout mismatch repair deficient cancer development and are recognized by tissue infiltrating T cells that are dysregulated in advanced lesions

Bibliographic Details
Main Authors:	Matthew Brown, Nina Bhardwaj, Cansu Cimen Bozkus, Aimee L Lucas, Alexandros D Polydorides, Leandra Velazquez, Mesude Bicak, Juhana Habib, Sharonne Holtzman, Mona Saleh, Robert Samstein
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
by: Vladimir Roudko, et al.
Published: (2021-09-01)

Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
by: Guillaume Mestrallet, et al.
Published: (2023-07-01)

Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
by: Milene Peterson, et al.
Published: (2020-05-01)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
by: Luhui Shen, et al.
Published: (2023-05-01)

Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer
by: Elisa De Paolis, et al.
Published: (2024-12-01)

A Thermosensitive Bi‐Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti‐Tumor Efficacy of Frameshift Neoantigens
by: Yaohua Ke, et al.
Published: (2024-04-01)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
by: Hiroaki Kanemura, MD, MPH, et al.
Published: (2022-08-01)

IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
by: Daniel Meraviglia-Crivelli, et al.
Published: (2022-11-01)

Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair–deficient colorectal cancer tissue
by: Tomomi Hirama, et al.
Published: (2021-07-01)

T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells
by: Peter Bauer, et al.
Published: (2022-12-01)

Lymphoma neoantigens
by: Joshua E. Elias
Published: (2018-06-01)

Indirectly recognized HLA-C mismatches and their potential role in transplant outcome
by: Kirsten Anne Thus, et al.
Published: (2014-05-01)

L138 F690 (138) [fotograf udara]

A frameshift in time
by: Martina M Yordanova, et al.
Published: (2022-04-01)

Autoimmunity: the neoantigen hypothesis
by: Tomas Mustelin, et al.
Published: (2024-06-01)

Neoantigens in Hematologic Malignancies
by: Melinda A. Biernacki, et al.
Published: (2020-02-01)

Determinants for Neoantigen Identification
by: Andrea Garcia-Garijo, et al.
Published: (2019-06-01)

Editorial 138
by: Miryam Colacrai, et al.
Published: (2023-12-01)

A138
by: K. Yurchenko, et al.
Published: (2015-11-01)

Presentación No. 138
by: El Editor
Published: (2017-02-01)

L138 F690 (138-150) [fotograf udara]

L138 F690 (138-150) [fotograf udara]

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
by: Ulla Kring Hansen, et al.
Published: (2020-03-01)

Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression
by: Stefani Spranger, et al.
Published: (2024-11-01)

Tumor neoantigens and tumor immunotherapies
by: Wang Jiani, et al.
Published: (2024-04-01)

The Neoantigen Landscape of Mycosis Fungoides
by: Arunima Sivanand, et al.
Published: (2020-11-01)

The Role of Neoantigens in Cancer Immunotherapy
by: Yueting Zhu, et al.
Published: (2021-08-01)

Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01)

413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors
by: Thomas Davis, et al.
Published: (2020-11-01)

Galactic production of 138La: Impact of 138,139La statistical properties
by: B.V. Kheswa, et al.
Published: (2015-05-01)

Reversible gene silencing through frameshift indels and frameshift scars provide adaptive plasticity for Mycobacterium tuberculosis
by: Aditi Gupta, et al.
Published: (2021-08-01)

P852: NEOANTIGENS PREDICTED BY THE GNE NEOANTIGEN PIPELINE IN PATIENTS DIAGNOSED WITH DE NOVO MULTIPLE MYELOMA
by: Y. Jiang, et al.
Published: (2022-06-01)

Neoantigen vaccine and neoantigen‐specific cell adoptive transfer therapy in solid tumors: Challenges and future directions
by: Yanwei Shen, et al.
Published: (2022-08-01)

Model of the pathway of –1 frameshifting: Kinetics
by: Ping Xie
Published: (2016-03-01)

On programmed ribosomal frameshifting: the alternative proteomes
by: Robin eKetteler
Published: (2012-11-01)

The highly conserved codon following the slippery sequence supports -1 frameshift efficiency at the HIV-1 frameshift site.
by: Suneeth F Mathew, et al.
Published: (2015-01-01)

Neoantigens: new hope for cancer therapy
by: Yitong Hu, et al.
Published: (2025-03-01)

Neoantigens as potential vaccines in hepatocellular carcinoma
by: Kathrin Heim, et al.
Published: (2022-02-01)

The Value of Microbes in Cancer Neoantigen Immunotherapy
by: Junrui Tian, et al.
Published: (2023-08-01)

Neoantigens: The Novel Precision Cancer Immunotherapy
by: Tiantian Zhang, et al.
Published: (2023-10-01)